Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme

7Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and high mortality, with no curative treatment to date as limited trafficking across the blood–brain barrier (BBB) combined with tumor heterogeneity often leads to therapeutic failure. Although modern medicine poses a wide range of drugs that are otherwise efficacious in treating other tumors, they often do not achieve therapeutic concentrations in the brain, hence driving the need for more effective drug delivery strategies. Nanotechnology, an interdisciplinary field, has been gaining immense popularity in recent years for remarkable advancements such as nanoparticle (NP) drug carriers, which possess extraordinary versatility in modifying surface coatings to home in on target cells, including those beyond the BBB. In this review, we will be highlighting recent developments in biomimetic NPs in GBM therapy and how these allowed us to overcome the physiological and anatomical challenges that have long plagued GBM treatment.

Cite

CITATION STYLE

APA

Lim, X. Y., Capinpin, S. M., Bolem, N., Foo, A. S. C., Yip, W. C. G., Kumar, A. P., & Teh, D. B. L. (2023, May 1). Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme. Bioengineering and Translational Medicine. John Wiley and Sons Inc. https://doi.org/10.1002/btm2.10483

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free